On January 28, 2024, Celltrion USA announced that it has completed submission of its application to the FDA for CT-P47, its proposed tocilizumab biosimilar. CT-P47 references.
EQS-News: Formycon AG / Key word(s): Study results/StudyAflibercept Biosimilar Candidate FYB203 shows comparable efficacy to the reference product Eylea®1 in Phase III Study 06.02.2023 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement.Press Release // February 6, 2023Aflibercept B.
DGAP-News: Formycon AG / Key word(s): Preliminary Results/Half Year ResultsFormycon publishes preliminary figures for the first half of 2022 06.09.2022 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement.Press Release // September 6, 2022 Formycon publishes preliminary fi.
DGAP-News: Formycon AG / Key word: AGM/EGM/Miscellaneous
Formycon AG announces amendment to the proposal for election of a Supervisory Board member in the context of the Annual General. | June 28, 2022